Cost Pressures Prompt Possible Fee Increases In Australia
Regulator Proposes Potentially Slower Drug Reviews Or Higher Fees
The Australian regulator, the TGA, is having to deal with increased cost pressures stemming from a rise in applications for unauthorized drugs, including medicinal cannabis.
You may also be interested in...
New medicines under evaluation at the European Medicines Agency.
The final text brings some changes, including the introduction of an escalation process when companies and NHS England cannot agree.
European industry association wants global convergence on development requirements, though the European Medicines Agency says that this would prove challenging.